Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc. is a pharmaceutical company based in Rockville, Maryland. The company employs 683 people and generates approximately $100 million in annual revenue. Supernus Pharmaceuticals Inc. focuses on developing and commercializing treatments for CNS diseases. The company markets a portfolio of prescription medications for a variety of neurological conditions. These include Qelbree®, for the treatment of ADHD in children, Trokendi XR® and Oxtellar XR® for epilepsy, Apokyn® for hypomobility in Parkinson’s disease, Myobloc® for cervical dystonia and sialorrhea, and Xadago® for Parkinson’s disease. Supernus Pharmaceuticals Inc. also sells its products through a dedicated sales force within the United States and partners with other pharmaceutical companies to license its products internationally. In addition to its marketed products, Supernus Pharmaceuticals Inc. has several product candidates under development. These include treatments for ADHD in adults, Parkinson’s disease hypomobility, treatment-resistant depression, and epilepsy. For more information about Supernus Pharmaceuticals Inc. and its products, visit supernus.com.